EP2597952A1 - Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties - Google Patents
Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell propertiesInfo
- Publication number
- EP2597952A1 EP2597952A1 EP11842977.8A EP11842977A EP2597952A1 EP 2597952 A1 EP2597952 A1 EP 2597952A1 EP 11842977 A EP11842977 A EP 11842977A EP 2597952 A1 EP2597952 A1 EP 2597952A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cancer
- cell
- stem cell
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/76—Agarose, agar-agar
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Definitions
- This invention relates to methods for isolating cancer stem cells, and the cancer stem cells thus isolated. It also relates to methods for screening compounds of interest to determine if they have potential efficacy as anti-tumor agents.
- CSC cancer stem cell
- 0CT4 octamer binding transcription factor 4
- 0CT4 octamer binding transcription factor 4
- Other transcription factors to induce adult cells to a pluripotent, stem cell like.
- 0CT4 octamer binding transcription factor 4
- Additional markers characteristic of stem cells may be found in, e.g, International Stem Cell Initiative, et al, Nat. Biotechnol 25(7):803- 16 (2007), incorporated by reference herein.
- the cells were stained with DAPI, to identify living cells, while standard immunochemical procedures were used to stain for OCT4, using a rabbit, polyclonal antibody to OCT4, and a goat, anti-IgG antibody labeled with a Fluor 488 conjugate.
- a requisite of cancer stem cells is the ability to form colonies of cancer cells. To determine if the cells described supra could do so, the colonies were dislodged from beads, and surviving cells were harvested, via mechanical disruption, 5-6 weeks after removal, and colonies were minced with forceps in RPMI 1640 plus 10% newborn calf serum. The suspension was then put through a 40 ⁇ cell strainer, so as to minimize any agarose debris, and pelleted via centrifugation. Cell pellets were resuspended, in naive culture medium and cultured either in vitro (200 cells/ml, in RPMI 1640 supplemented with 10% newborn calf serum), or cultured in vivo.
- RENCA cells grown in vitro were much larger than normal RENCA cells which were grown in monolayer, and they were not observed to undergo cell growth for about 16 weeks. It 16-17 weeks post-culture, cells formed plaques and begun proliferating upon weekly passage, and growing as a monolayer in culture. But two weeks after the start of monolayer growth, these cells had growth rates which were comparable to normal RENCA cells, and appeared as normal RENCA monolayer cells, with equivalent size and morphology.
- mice which received implants one developed a tumor under the capsule, and died 98 days post-induction. It had also developed a lung metastasis.
- the foregoing examples set forth various aspects of the invention, which include a method for isolating cancer cells which are resistant to chemotherapeutic agents, such as Docetaxel, and which possess one or more properties of stem cells, such as expression of OCT4. Other properties of stem cells are well known to the art and are not repeated here.
- the method involves encapsulating a sample of cancer cells in an agarose containing bead which is then coated with agarose, culturing the resulting bead to grow the cancer cells contained therein, contacting the bead with a chemotherapeutic agent, and determining which of said remaining cells express OCT4, either in situ or by removal therefrom.
- This method can be used, e.g., to develop a prognosis for a subject suffering from cancer, because as noted supra, cells of the type described herein are responsible for recurrence of cancer in subjects. Essentially, a high percentage of said cells indicates a poorer prognosis for a patient than would be the case for a patient who exhibits few, or no such cells in the encapsulated sample.
- Any chemotherapeutic agent may be used in the method of the invention, as can any type of cancer. The skilled artisan will be aware of many other known therapeutic agents for cancer therapy. Similarly, it will be recognized from, e.g., the references cited supra, that various cancers and agaroses may be used, in addition to those described herein. Also, the beads of the invention may include materials such as collagen, or other materials compatible with agarose.
- the cancer cells are preferably mammalian cells, and most preferably, human cells.
- Such cells are isolated cancer cells which are resistant to chemotherapeutic agents, such as Docetaxel, and which express OCT4.
- the substance of interest may be tested against the stem-cell like cancer cells remaining after the contact with the first agent, or one may encapsulate a separate sample of stem cell like cancer cells and proceed in the same fashion.
- the invention relates to a method for determining if a compound of interest has efficacy as an anti-cancer agent.
- the method involves contacting a compound of interest to an agarose coated, agarose bead, which contains a sample of cancer cells, for a chosen period of time and at a chosen concentration, and determining if said compound destroys a percentage of cells greater than a control.
- the compound may be considered to be therapeutically useful, as well as useful in non-therapeutic contexts, such as use in destroying cancer cells in a mixed cell population, or in eliminating no n- stem cell cancer cells from a mix of cells.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14171733.0A EP2777398B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
DK14171733.0T DK2777398T3 (en) | 2010-11-23 | 2011-11-22 | Method for Isolating a Cancer Cell with Stem Cell Properties Resistant to Chemotherapeutic Agent |
PL11842977T PL2597952T3 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45839010P | 2010-11-23 | 2010-11-23 | |
US45839110P | 2010-11-23 | 2010-11-23 | |
PCT/US2011/061812 WO2012071394A1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14171733.0A Division EP2777398B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
EP14171733.0A Division-Into EP2777398B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2597952A1 true EP2597952A1 (en) | 2013-06-05 |
EP2597952A4 EP2597952A4 (en) | 2014-01-22 |
EP2597952B1 EP2597952B1 (en) | 2015-01-07 |
Family
ID=46146185
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14171733.0A Active EP2777398B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
EP11842977.8A Active EP2597952B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14171733.0A Active EP2777398B1 (en) | 2010-11-23 | 2011-11-22 | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties |
Country Status (20)
Country | Link |
---|---|
US (2) | US8741637B2 (en) |
EP (2) | EP2777398B1 (en) |
JP (1) | JP5899230B2 (en) |
KR (1) | KR101874654B1 (en) |
CN (1) | CN103108547B (en) |
AP (1) | AP3446A (en) |
AU (1) | AU2011332020B2 (en) |
BR (1) | BR112013012710B1 (en) |
CA (1) | CA2801370C (en) |
DK (2) | DK2777398T3 (en) |
ES (2) | ES2534374T3 (en) |
HK (1) | HK1179827A1 (en) |
HU (1) | HUE035164T2 (en) |
IL (2) | IL223362A (en) |
MX (1) | MX2013005836A (en) |
NZ (1) | NZ603949A (en) |
PL (2) | PL2777398T3 (en) |
PT (2) | PT2777398T (en) |
RU (1) | RU2583296C2 (en) |
WO (1) | WO2012071394A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888487A (en) * | 1995-03-29 | 1999-03-30 | Henkel Kommanditgesellschaft Auf Aktien | Low-viscosity opacifier concentrates |
WO2009098698A2 (en) * | 2008-02-07 | 2009-08-13 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
US7704967B2 (en) * | 2006-03-14 | 2010-04-27 | University Of Maryland, Baltimore | TFIIS and GDOWN1 as targets for cancer therapy |
US20100273160A1 (en) * | 2007-07-17 | 2010-10-28 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6224912B1 (en) | 1996-04-03 | 2001-05-01 | The Rogo Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
US7297331B2 (en) | 1996-04-03 | 2007-11-20 | The Rogosin Institute | Beads containing restricted cancer cells producing material suppressing cancer cell proliferation |
US5888497A (en) * | 1996-04-03 | 1999-03-30 | The Rogosin Institute | Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation |
US6303151B1 (en) | 1996-04-03 | 2001-10-16 | The Rogosin Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
US20050053586A1 (en) * | 2003-09-04 | 2005-03-10 | Bryan Conn | Entrapped stem cells and uses thereof |
JP4937265B2 (en) | 2005-09-26 | 2012-05-23 | ザ・ロゴシン・インスティテュート・インコーポレイテッド | Secreted cell-containing macrobeads containing Seek Gold Agarose |
WO2007118242A2 (en) * | 2006-04-07 | 2007-10-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of a constitutively resistant cancer stem cell |
KR100783199B1 (en) * | 2006-05-18 | 2007-12-06 | 부산대학교 산학협력단 | New cancer stem cell line GBM 2 established from human Glioblastoma multiforme tissue |
EP2783700A1 (en) * | 2006-09-07 | 2014-10-01 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
US8674172B2 (en) * | 2009-04-14 | 2014-03-18 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
WO2010124498A1 (en) * | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
-
2011
- 2011-11-22 PT PT141717330T patent/PT2777398T/en unknown
- 2011-11-22 ES ES11842977.8T patent/ES2534374T3/en active Active
- 2011-11-22 JP JP2013540108A patent/JP5899230B2/en not_active Expired - Fee Related
- 2011-11-22 WO PCT/US2011/061812 patent/WO2012071394A1/en active Application Filing
- 2011-11-22 NZ NZ603949A patent/NZ603949A/en unknown
- 2011-11-22 EP EP14171733.0A patent/EP2777398B1/en active Active
- 2011-11-22 EP EP11842977.8A patent/EP2597952B1/en active Active
- 2011-11-22 CN CN201180031067.6A patent/CN103108547B/en active Active
- 2011-11-22 ES ES14171733.0T patent/ES2632066T3/en active Active
- 2011-11-22 HU HUE14171733A patent/HUE035164T2/en unknown
- 2011-11-22 BR BR112013012710-4A patent/BR112013012710B1/en active IP Right Grant
- 2011-11-22 PT PT118429778T patent/PT2597952E/en unknown
- 2011-11-22 AU AU2011332020A patent/AU2011332020B2/en active Active
- 2011-11-22 DK DK14171733.0T patent/DK2777398T3/en active
- 2011-11-22 CA CA2801370A patent/CA2801370C/en active Active
- 2011-11-22 AP AP2013006904A patent/AP3446A/en active
- 2011-11-22 MX MX2013005836A patent/MX2013005836A/en active IP Right Grant
- 2011-11-22 KR KR1020137002954A patent/KR101874654B1/en active IP Right Grant
- 2011-11-22 DK DK11842977T patent/DK2597952T3/en active
- 2011-11-22 US US13/701,705 patent/US8741637B2/en active Active
- 2011-11-22 RU RU2012151922/10A patent/RU2583296C2/en active
- 2011-11-22 PL PL14171733T patent/PL2777398T3/en unknown
- 2011-11-22 PL PL11842977T patent/PL2597952T3/en unknown
-
2012
- 2012-11-29 IL IL223362A patent/IL223362A/en active IP Right Grant
-
2013
- 2013-06-21 HK HK13107275.6A patent/HK1179827A1/en unknown
-
2014
- 2014-04-25 US US14/262,232 patent/US9375448B2/en active Active
- 2014-06-18 IL IL233227A patent/IL233227A/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888487A (en) * | 1995-03-29 | 1999-03-30 | Henkel Kommanditgesellschaft Auf Aktien | Low-viscosity opacifier concentrates |
US7704967B2 (en) * | 2006-03-14 | 2010-04-27 | University Of Maryland, Baltimore | TFIIS and GDOWN1 as targets for cancer therapy |
US20100273160A1 (en) * | 2007-07-17 | 2010-10-28 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
WO2009098698A2 (en) * | 2008-02-07 | 2009-08-13 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
Non-Patent Citations (8)
Title |
---|
B. H. SMITH ET AL: "Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth", CANCER RESEARCH, vol. 71, no. 3, 24 January 2011 (2011-01-24), pages 725-735, XP055093632, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-2258 * |
B. H. SMITH ET AL: "Three-Dimensional Culture of Mouse Renal Carcinoma Cells in Agarose Macrobeads Selects for a Subpopulation of Cells with Cancer Stem Cell or Cancer Progenitor Properties", CANCER RESEARCH, vol. 71, no. 3, 1 February 2011 (2011-02-01), pages 716-724, XP055050161, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-2254 * |
CHAUCHEREAU A ET AL: "Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 317, no. 3, 23 January 2010 (2010-01-23), pages 262-275, XP027558834, ISSN: 0014-4827 [retrieved on 2010-12-14] * |
ELAINE LAI-HAN LEUNG ET AL: "Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties", PLOS ONE, vol. 5, no. 11, 19 November 2010 (2010-11-19), page e14062, XP055093684, DOI: 10.1371/journal.pone.0014062 * |
GURSKI L A ET AL: "Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 30, 1 October 2009 (2009-10-01), pages 6076-6085, XP026524674, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2009.07.054 [retrieved on 2009-08-19] * |
HARMA VILLE ET AL: "A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 5, 1 May 2010 (2010-05-01), XP009158800, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0010431 * |
L. MA ET AL: "Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3", ACTA BIOCHIMICA ET BIOPHYSICA SINICA, vol. 42, no. 9, 12 August 2010 (2010-08-12), pages 593-602, XP055093702, ISSN: 1672-9145, DOI: 10.1093/abbs/gmq067 * |
See also references of WO2012071394A1 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20140020863A (en) | Tumour cell and tissue culture | |
US20200347361A1 (en) | Methods of Primary Tissue Culture and Drug Screening Using Autologous Serum and Fluids | |
KR20210099208A (en) | Composition for regenerating normal tissue from fibrotic tissue | |
WO2011149013A1 (en) | Method for evaluation of sensitivity of cancer-tissue-derived cell mass or aggregated cancer cell mass to medicinal agent or radioactive ray | |
WO2012135588A2 (en) | Methods of treating serosal cancer | |
KR20150084688A (en) | Method of Screening an Agent for Preventing or Treating Cancer Using Morphology of Luterial | |
JP5809782B2 (en) | Method for evaluating drug or radiosensitivity of cancer tissue-derived cell mass or cancer cell aggregate | |
AU2011332020B2 (en) | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties | |
AU2014202491B2 (en) | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties | |
OA17846A (en) | Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties. | |
US20140128272A1 (en) | Method for Inducing Dormancy of Cancer Tissue-Derived Cell Mass and Method for Evaluating Treating Means with the Use of Cancer-Tissue-Derived Cell Mass | |
JP2019198252A (en) | Renal proximal tubule epithelial cell and use of the same | |
Gao et al. | The Influence of L-arginine on Cell Proliferation, iNOS Expression and Cell Cycle in the Human Colon Carcinoma Cell Line LS174 | |
Jandial | Lineage mapping of brain tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130301 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140107 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/095 20100101ALI20131219BHEP Ipc: A01N 43/02 20060101AFI20131219BHEP Ipc: G01N 33/543 20060101ALI20131219BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140408 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140724 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 705032 Country of ref document: AT Kind code of ref document: T Effective date: 20150215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011013071 Country of ref document: DE Effective date: 20150305 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20150324 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KEMIA SA, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2534374 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150422 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20150320 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20150400708 Country of ref document: GR Effective date: 20150421 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20150107 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150407 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150507 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011013071 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
26N | No opposition filed |
Effective date: 20151008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: IPWAY DI FRANCESCO FABIO AND CO., CH |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20161104 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20111122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150107 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20221127 Year of fee payment: 12 Ref country code: PT Payment date: 20221103 Year of fee payment: 12 Ref country code: NO Payment date: 20221125 Year of fee payment: 12 Ref country code: NL Payment date: 20221126 Year of fee payment: 12 Ref country code: LU Payment date: 20221128 Year of fee payment: 12 Ref country code: IT Payment date: 20221123 Year of fee payment: 12 Ref country code: IE Payment date: 20221128 Year of fee payment: 12 Ref country code: GB Payment date: 20221128 Year of fee payment: 12 Ref country code: FR Payment date: 20221123 Year of fee payment: 12 Ref country code: FI Payment date: 20221125 Year of fee payment: 12 Ref country code: ES Payment date: 20221201 Year of fee payment: 12 Ref country code: DK Payment date: 20221125 Year of fee payment: 12 Ref country code: DE Payment date: 20221125 Year of fee payment: 12 Ref country code: CZ Payment date: 20221108 Year of fee payment: 12 Ref country code: AT Payment date: 20221102 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20221031 Year of fee payment: 12 Ref country code: GR Payment date: 20221129 Year of fee payment: 12 Ref country code: CH Payment date: 20221205 Year of fee payment: 12 Ref country code: BE Payment date: 20221128 Year of fee payment: 12 |